PMID- 38274976
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240128
IS  - 0973-6247 (Print)
IS  - 1998-3565 (Electronic)
IS  - 0973-6247 (Linking)
VI  - 17
IP  - 2
DP  - 2023 Jul-Dec
TI  - A retrospective study to assess the impact of ABO incompatibility on outcomes of 
      allogeneic peripheral blood stem cell transplants at a tertiary care hospital in 
      Western Maharashtra.
PG  - 202-209
LID - 10.4103/ajts.ajts_134_21 [doi]
AB  - BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has emerged as a 
      curative measure for life-threatening hematological disorders. It can be 
      autologous or allogeneic depending on the disease characteristics. Providing 
      transfusion support to the transplant patients can be challenging, especially in 
      AB-mismatched allogeneic HSCT. In this study, we investigated the impact of ABO 
      incompatibility in patients undergoing allogeneic HSCT. MATERIALS AND METHODS: A 
      retrospective review was conducted in 76 patients with hematological diseases who 
      underwent allogeneic HSCT. Transfusion requirements, engraftment profile, 
      incidence of graft versus host disease (GvHD), and mortality for a period of 1 
      year were analyzed. RESULTS: ABO incompatibility between donor and the patient 
      did not significantly affect the neutrophil and platelet (PLT) engraftment time 
      (P = 0.389, 0.349, respectively), packed red blood cells transfusion requirement, 
      and duration of initial hospital stay. However, patients of ABO-incompatible HSCT 
      received more PLT transfusions posttransplant which was statistically 
      significant. 29.1% of ABO compatible and 16.7% incompatible HSCT patients 
      developed GVHD. Mortality rates in the two groups were 16.7% and 8.3%, 
      respectively. However, differences in both the parameters were not statistically 
      significant. CONCLUSION: Our study showed that ABO incompatibility does not 
      significantly affect the outcome and should not be a limiting factor for 
      selection of donor. Donor availability and human leukocyte antigen (HLA) matching 
      remain the critical selection criteria.
CI  - Copyright: (c) 2022 Asian Journal of Transfusion Science.
FAU - Nalukettil, Balu B
AU  - Nalukettil BB
AD  - Department of Immunohematology and Blood Transfusion, Armed Forces Medical 
      College, Pune, Maharashtra, India.
FAU - Biswas, Amit Kumar
AU  - Biswas AK
AD  - Department of Immunohematology and Blood Transfusion, Armed Forces Medical 
      College, Pune, Maharashtra, India.
FAU - Asthana, Bhushan
AU  - Asthana B
AD  - Department of Pathology, Command Hospital (SC), Pune, Maharashtra, India.
FAU - Kushwaha, Neerja
AU  - Kushwaha N
AD  - Department of Lab Sciences, Lucknow, Uttar Pradesh, India.
FAU - Baranwal, Ajay Kumar
AU  - Baranwal AK
AD  - Department of Immunohematology and Blood Transfusion, Armed Forces Medical 
      College, Pune, Maharashtra, India.
FAU - Sharma, Sanjeevan
AU  - Sharma S
AD  - Department of Clinical Hematology, Command Hospital, Lucknow, Uttar Pradesh, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20220526
PL  - India
TA  - Asian J Transfus Sci
JT  - Asian journal of transfusion science
JID - 101306858
PMC - PMC10807530
OTO - NOTNLM
OT  - ABO incompatibility
OT  - allogeneic stem cell transplant
OT  - transplant outcome
COIS- There are no conflicts of interest.
EDAT- 2024/01/26 06:43
MHDA- 2024/01/26 06:44
PMCR- 2023/07/01
CRDT- 2024/01/26 04:01
PHST- 2021/09/09 00:00 [received]
PHST- 2021/10/21 00:00 [revised]
PHST- 2021/11/06 00:00 [accepted]
PHST- 2024/01/26 06:44 [medline]
PHST- 2024/01/26 06:43 [pubmed]
PHST- 2024/01/26 04:01 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - AJTS-17-202 [pii]
AID - 10.4103/ajts.ajts_134_21 [doi]
PST - ppublish
SO  - Asian J Transfus Sci. 2023 Jul-Dec;17(2):202-209. doi: 10.4103/ajts.ajts_134_21. 
      Epub 2022 May 26.